Antioxidative Effect of Hydroalcoholic Extracts of Fruit and Pit of Elaeagnud Angosifolia Against Oxidative Stress Markers in Benign Prostatic Hyperplasia

Background & aim: The use of medicinal plants has been common among people since ancient times, and in recent years special attention has been paid to their therapeutic consumption. As oxidative stress is one of the possible causes of benign prostatic hyperplasia, the aim of the present study was to determine and compare the antioxidative effect of hydroalcoholic extracts of fruit and pit of Elaeagnud angosifolia against oxidative stress markers in benign prostatic hyperplasia. Methods: In the present semi-experimental study conducted in 2021 at Yasuj University of Medical Sciences, 96 patients over 45 years of age with benign prostatic hyperplasia with International Prostate Symptoms Score (IPSS) below 20 were randomly assigned to two groups receiving placebo (600 mg of white wheat flour for one month) and drug (600 mg of hydroalcoholic extract of elderberry for one month). Blood samples were taken from each patient before and after the study to check the level of oxidative stress factors, including total thiol (TSH), total plasma antioxidant capacity (FRAP), malondialdehyde (MDA) and nitric oxide (NO) metabolites, and at the end of the study, was evaluated. The collected data were analyzed using t-test, Will-Coxon and Mann-Whitney tests. Results: The results of the present study indicated that the hydroalcoholic extract of elderberry kernel and fruit increased the MDA level in the group receiving the extract (480.7±65 vs. 457.8±51) compared to the placebo group (454.8±50 vs. 36±36). 447/3) decreased, however, this decrease was not significant. Also, the amount of NO metabolites in the group receiving the hydroalcoholic extract of elderberry kernel and fruit (6.7±7.8 to 15.7±9) compared to the placebo group (5.5±3 versus 16.6±9) indicated a lower increase. This increase was correspondingly not significant. In addition, there was no statistically significant difference in the amount of FRAP and TSH between the drug and placebo groups (p